JP2008509928A5 - - Google Patents

Download PDF

Info

Publication number
JP2008509928A5
JP2008509928A5 JP2007525838A JP2007525838A JP2008509928A5 JP 2008509928 A5 JP2008509928 A5 JP 2008509928A5 JP 2007525838 A JP2007525838 A JP 2007525838A JP 2007525838 A JP2007525838 A JP 2007525838A JP 2008509928 A5 JP2008509928 A5 JP 2008509928A5
Authority
JP
Japan
Prior art keywords
use according
methylene
tetraazacyclotetradecanyl
phenylenebis
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007525838A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008509928A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/028783 external-priority patent/WO2006020891A2/en
Publication of JP2008509928A publication Critical patent/JP2008509928A/ja
Publication of JP2008509928A5 publication Critical patent/JP2008509928A5/ja
Withdrawn legal-status Critical Current

Links

JP2007525838A 2004-08-13 2005-08-11 前駆／幹細胞を動員するためのケモカインの組み合わせ Withdrawn JP2008509928A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60136704P 2004-08-13 2004-08-13
PCT/US2005/028783 WO2006020891A2 (en) 2004-08-13 2005-08-11 Chemokine combinations to mobilize progenitor/stem cells

Publications (2)

Publication Number Publication Date
JP2008509928A JP2008509928A (ja) 2008-04-03
JP2008509928A5 true JP2008509928A5 (https=) 2008-10-09

Family

ID=35908186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007525838A Withdrawn JP2008509928A (ja) 2004-08-13 2005-08-11 前駆／幹細胞を動員するためのケモカインの組み合わせ

Country Status (9)

Country Link
US (1) US20060035829A1 (https=)
EP (1) EP1796716A4 (https=)
JP (1) JP2008509928A (https=)
CN (1) CN101094684A (https=)
AU (1) AU2005272653A1 (https=)
BR (1) BRPI0514343A (https=)
CA (1) CA2577046A1 (https=)
TW (1) TW200608991A (https=)
WO (1) WO2006020891A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435939B2 (en) * 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US20070043012A1 (en) * 2005-08-19 2007-02-22 Bridger Gary J Methods to enhance chemotherapy
CA2643209A1 (en) * 2006-02-24 2007-09-20 Genzyme Corporation Methods for increasing blood flow and/or promoting tissue regeneration
WO2007132846A1 (ja) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. 保護されていてもよい酸性基を含有する化合物およびその用途
JP5245827B2 (ja) 2006-07-31 2013-07-24 小野薬品工業株式会社 スピロ結合した環状基を含有する化合物およびその用途
US20100003224A1 (en) * 2006-08-02 2010-01-07 Genzyme Corporation Combination Therapy
WO2008075371A2 (en) * 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
BRPI1009663A2 (pt) * 2009-06-14 2016-10-11 Biokine Therapeutics Ltd "método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica"
KR20140045411A (ko) 2011-05-16 2014-04-16 젠자임 코포레이션 Ｃｘｃｒ４ 길항제의 용도
CN103159690B (zh) * 2011-12-14 2015-03-25 朱靖华 对称大环胺化合物的结晶形式
EP2841084B1 (en) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer
KR102083046B1 (ko) * 2012-06-07 2020-02-28 칠드런＇스 하스피틀 로스 앤젤레스 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법
KR102503695B1 (ko) * 2013-02-28 2023-02-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 줄기세포를 동원하기 위한 방법 및 조성물
MX2016010699A (es) 2014-02-18 2017-10-11 Children's Hospital Los Angeles Composiciones y metodos para tratar neutropenia.
EP3302710A4 (en) * 2015-06-03 2019-02-20 The University of Queensland MOBILIZERS AND USE THEREOF
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
KR102033920B1 (ko) 2016-02-23 2019-10-18 바이오라인알엑스 리미티드 급성 골수성 백혈병을 치료하는 방법
EP3419617A4 (en) * 2016-02-26 2019-10-23 President and Fellows of Harvard College HIGH GRADE TRANSPLANTABLE HEMATOPOETIC STEM CELLS
WO2018085574A2 (en) * 2016-11-02 2018-05-11 Washington University Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof
TW201841916A (zh) 2017-04-12 2018-12-01 美商麥珍塔治療學股份有限公司 芳香烴受體拮抗劑及其用途
US20190314407A1 (en) 2017-10-31 2019-10-17 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
EP3703715A1 (en) 2017-10-31 2020-09-09 Magenta Therapeutics, Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
CN111712262A (zh) * 2017-12-06 2020-09-25 美真达治疗公司 用于动员造血干细胞和祖细胞的给药方案
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US20200338132A1 (en) 2018-01-03 2020-10-29 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
EP4051298A1 (en) 2019-11-01 2022-09-07 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
CA3176979A1 (en) 2020-04-27 2021-11-04 Anthony Boitano Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
WO2022197776A1 (en) 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
CN116789639A (zh) * 2022-03-14 2023-09-22 上海医药工业研究院有限公司 Mavorixafor的纯化方法、其盐及有关物质

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680174A (en) * 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
ES2210255T3 (es) * 1993-06-08 2004-07-01 Smithkline Beecham Corporation Metodos para mejorar la actividad biologica de quimiocinas.
DE4320478B4 (de) * 1993-06-21 2007-11-15 Robert Bosch Gmbh Fahrstabilitätsregler
EP0741580A4 (en) * 1993-12-14 2001-07-11 Univ Johns Hopkins Med Controlled release of pharmaceutically active substances for immunotherapy
GB9400411D0 (en) * 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US6713052B1 (en) * 1995-10-24 2004-03-30 Human Genome Sciences, Inc. Method of mobilizing stem cells with chemokine β-8
EP1016726A1 (en) * 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
AU2334301A (en) * 1999-12-17 2001-06-25 Anormed Inc. Chemokine receptor binding heterocyclic compounds
HK1052011A1 (zh) * 2000-09-15 2003-08-29 Anormed Inc. 趋化因子受体结合杂环化合物
DE60137435D1 (de) * 2000-09-15 2009-03-05 Anormed Inc Chemokin rezeptor bindenden heterozyklische verbindungen
US6734191B2 (en) * 2000-09-15 2004-05-11 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
DE60136476D1 (de) * 2000-09-29 2008-12-18 Anormed Inc -stickstoffhaltigen zyklischen polyaminen und deren verbindungen
WO2002081727A2 (en) * 2001-04-03 2002-10-17 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
DK1411918T3 (da) * 2001-07-31 2012-04-23 Genzyme Global S A R L Fremgangsmåder til at mobilisere progenitor/stamceller
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
CN100463962C (zh) * 2001-12-07 2009-02-25 图尔金株式会社 嵌合蛋白质的表型筛选
WO2004091518A2 (en) * 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
JP4778420B2 (ja) * 2003-04-22 2011-09-21 アノーメッド インコーポレイティド 増強された有効性を有するケモカインレセプタ結合複素環式化合物
EP1708703A4 (en) * 2003-12-11 2008-04-09 Anormed Inc CHEMOKIN RECEPTOR BINDING COMPOUNDS

Similar Documents

Publication Publication Date Title
JP2008509928A5 (https=)
US12037321B2 (en) 1,2,4-oxadiazole derivatives as immunomodulators
CN1561208B (zh) 活化祖细胞/干细胞的方法
JP2002536329A5 (https=)
JP2014513727A5 (https=)
JP2008528658A5 (https=)
JP2017533922A5 (https=)
JP2008195730A5 (https=)
JP2019089794A (ja) 治療薬を局所的送達するための化学構造
JP2017511360A5 (https=)
JP2011006428A5 (https=)
CA2361587A1 (en) Methods and compositions to enhance white blood cell count
RU2010113982A (ru) Применение пептида в качестве терапевтического средства
JP2022095872A5 (https=)
US20240158445A1 (en) Cyclic cell-penetrating peptides with three or more hydrophobic residues
CN101495115A (zh) 组合治疗
AU2016202594B2 (en) Scheme for administering N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)­benzofuran-2-ylcarbonylamino]ethoxy}benzamide
RU2014124171A (ru) Лекарственное средство для терапевтического лечения и/или улучшения состояния при сепсисе
MY145838A (en) Powder formulations for inhalation, comprising enantiomerically pure beta agonists
JP2005527479A5 (https=)
CN101175490B (zh) 循环障碍改善剂
JP2008520682A (ja) ヒストンデアセチラーゼ阻害剤およびその使用方法
EP1345604B1 (en) Use of a alpha-halogen-acryloyl distamycin derivate for the preparation of a medicament for the treatment of cancer
ES2910654T3 (es) Composiciones y métodos para mejorar la migración y el injerto de células madre hematopoyéticas
WO2008113095A1 (en) Compositions and therapies comprising tranilast compounds and angiotensin-converting enzyme (ace) inhibitors and/or angiotensin receptor blockers (arb)